Sierra Oncology
1820 Gateway Drive
Suite 110
San Mateo
California
94404
United States
Tel: 650-376-8679
Website: https://sierraoncology.com/
About Sierra Oncology
194 articles about Sierra Oncology
-
Sierra Announces Promising Preliminary Efficacy in SRA737 Clinical Program & Outlines Potential Path to Registration
6/1/2019
Sierra Oncology, Inc. reported positive preliminary clinical data from its two first-in-human Phase 1/2 studies of SRA737, a highly selective oral Chk1 inhibitor, as monotherapy and as SRA737+LDG (SRA737 potentiated by low dose gemcitabine), at the 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
-
Sierra Oncology to Present Momelotinib and SRA737 Overview at the Jefferies Global Healthcare Conference in New York
5/28/2019
Sierra Oncology, Inc. announced that Dr. Nick Glover, President and Chief Executive Officer, will present an overview of the company and updates concerning its clinical stage drug candidates, momelotinib and SRA737, at 8:00 am ET on Wednesday, June 5 at the Jefferies Global Healthcare Conference being held in New York.
-
Sierra Oncology Reports First Quarter 2019 Results
5/8/2019
Sierra Oncology, Inc. reported its financial and operational results for the first quarter ended March 31, 2019.
-
Sierra Oncology to Attend Two Investor Conferences in May
5/6/2019
Sierra Oncology, Inc. announced that members of its senior management team will be attending the SunTrust Robinson Humphrey 5th Annual Life Sciences Conference in New York on May 8th, and the Oppenheimer Oncology Insight Summit in New York on May 16th.
-
Sierra Reports Late-Breaking SRA141 Preclinical Data in Poster at AACR 2019
4/3/2019
Compelling preclinical data for its Cdc7 inhibitor, SRA141, indicate a potentially novel and distinct mechanism of action
-
Sierra Reports Late-Breaking Preclinical Data for SRA737 Presented at AACR 2019
4/1/2019
Late-breaking oral presentation reports profound, durable synergistic activity for immunotherapy combined with SRA737+LDG, its Chk1 inhibitor plus low dose gemcitabine (LDG), in small cell lung cancer models
-
Sierra Oncology to Present at the Cowen 39th Annual Health Care Conference in Boston
3/5/2019
Dr. Christian Hassig, CSO, scheduled to present at 10:00 a.m. ET on March 13, 2019
-
Sierra Oncology Reports 2018 Year End Results
2/28/2019
Sierra Oncology, Inc. reported its financial and operational results for the year ended December 31, 2018.
-
Sierra Oncology Announces Late-Breaking Oral and Poster Presentations at AACR 2019 for SRA737 and SRA141 Preclinical Data
2/27/2019
Late-breaking oral presentation to report preclinical mechanistic and efficacy data for immunotherapy combined with SRA737 + LDG, its Chk1 inhibitor plus low dose gemcitabine (LDG), in small cell lung cancer models
-
Sierra Oncology to Present at the DNA Damage Response Therapeutics Summit on January 30, 2019
1/23/2019
"Addressing Intrinsic & Acquired PARP Inhibitor Resistance Through Chk1 Inhibition" scheduled for 9:00 am ET on January 30 in Boston
-
Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib
12/3/2018
44% of transfusion dependent myelofibrosis patients (multi-study aggregate N=152) were transfusion free for at least 12 weeks; 49% were transfusion free for at least 8 weeks
-
Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
11/29/2018
SRA737 synergizes with immune checkpoint blockade in small cell lung cancer (SCLC)
-
Sierra Oncology to Host Analyst Call Highlighting Clinical Data on Momelotinib's Anemia Benefit
11/27/2018
Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, today announced that it will host an Analyst & Investor call on Monday, December 3rd
-
Sierra Oncology Reports Preclinical Efficacy for Chk1 inhibitor SRA737 in Treatment Refractory Ovarian Cancer Models at the EORTC-NCI-AACR Symposium
11/15/2018
SRA737 demonstrates preclinical efficacy in aggressive CCNE1-amplified and MYCN‑overexpressing high-grade serous ovarian cancer patient-derived xenograft (PDX) models
-
Sierra Oncology Reports SRA141 Preclinical Efficacy at EORTC-NCI-AACR Symposium
11/13/2018
Novel oral Cdc7 inhibitor, SRA141, demonstrates competitive target selectivity and robust efficacy in several cancer models.
-
Sierra Oncology Reports Third Quarter 2018 Results
11/8/2018
Momelotinib regulatory pathway clarity anticipated in H1 2019
-
Sierra Oncology to Present at the Jefferies 2018 London Healthcare Conference
11/7/2018
"Targeted Therapeutics for Hematology & Oncology" scheduled for 5:20 p.m. GMT on November 14, 2018
-
Sierra Oncology to Report Clinical Data at ASH 2018 from Translational Biology Study of Momelotinib in Transfusion Dependent Patients
11/1/2018
Sierra Oncology (Nasdaq: SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, today reported that clinical data from a translational biology study of momelotinib in 41 transfusion dependent patients with myelofibrosis (MF) will be reported in a poster at ASH 2018.
-
Sierra Oncology to Host KOL Call with Dr. Srdan Verstovsek Presenting "Unmet Medical Needs in Myelofibrosis"
10/4/2018
Sierra Oncology, Inc. today announced that it will host a Key Opinion Leader call on the topic of "Unmet Medical Needs in Myelofibrosis" on Wednesday, October 17 at 10:30 am Eastern Time.
-
Sierra Oncology Obtains Debt Facility from Silicon Valley Bank to Acquire and Advance Momelotinib
8/22/2018
Up to $15 million available in three $5 million tranches; additional $25 million potentially available